Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)/Dysplasia Panel
Use
This test is designed for individuals with relevant clinical features or a suspected diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D). It is also suitable for those with a family history of ARVC/D. The panel can help confirm a clinical diagnosis and assist in genetic counseling for family members. This testing can help determine an individual’s risk of developing the condition.
Special Instructions
The Exome Platform allows for varied specimen types including blood, DNA, buccal, saliva, and tissue, while the Genome Platform only accepts blood and DNA. It is important to follow the specimen collection and handling instructions precisely to ensure accurate testing results. STAT testing options are available, which could expedite the process but come with a surcharge.
Limitations
This test has not been cleared or approved by the US Food and Drug Administration. Results should be interpreted in conjunction with clinical findings and family history. The test is developed under CAP and CLIA regulations but may not capture all mutations, especially those outside the targeted regions or with low penetration rates.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided